Jade Biosciences, Inc. (JBIO): R&D Expense
$93.12M
Year ended 2025-12-31
$136.67M
Trailing 12 months to 2026-06-30
+34.1%
3-year compound annual growth
+63.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.12M | +75.1% | 2026-03-06, From 2025-01-01 |
| 2024-12-31 | $53.19M | -17.2% | 2025-03-27, From 2024-01-01 |
| 2023-12-31 | $64.22M | +66.3% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $38.62M | +157.7% | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | $14.99M | +88.8% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $7.94M | n/a | 2022-03-30, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | 2025-12-31 | $93.12M | +75.1% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $137.00M | +1.8% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $136.81M | +117.3% |
| Capricor Therapeutics, Inc. (CAPR) | 2025-12-31 | $84.45M | +69.0% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $158.68M | -7.5% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $129.64M | -25.3% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $135.97M | -17.0% |
| Fulcrum Therapeutics, Inc. (FULC) | 2025-12-31 | $56.10M | -11.5% |
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $153.35M | +94.1% |
Compare JBIO, ZYME, UPB, CAPR side by side · Screen every company in Pharmaceutical Preparations ↗